Product Description
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Bristol-Myers Squibb presented P3 Renal Cell Carcinoma results on 2024-01-22 for Nivocasan
Highest Development Phases
Phase 2: Communicable Diseases|Hepatitis C, Chronic|Liver Cirrhosis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12619000679189p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Dementia|Depressive Disorder |
None |
|||
2008-007456-96 |
2008-007456-96 | P2 |
Completed |
Hepatitis C, Chronic |
2010-07-20 |
2022-03-13 |
Treatments |
|
NCT00874796 |
GS-US-227-0106 | P2 |
Terminated |
Hepatitis C, Chronic|Communicable Diseases |
2010-04-01 |
2019-03-18 |
Treatments |
|
2008-002361-31 |
2008-002361-31 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2009-08-05 |
2022-03-12 |
Treatments |
|
NCT00740610 |
GS-US-228-0101 | P2 |
Completed |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2009-08-01 |
2019-03-18 |
Treatments |
|
2007-001601-16 |
2007-001601-16 | P2 |
Completed |
Hepatitis C, Chronic |
2009-03-31 |
2022-03-12 |
Treatments |
|
NCT00725803 |
GS-US-227-0102 | P2 |
Completed |
Hepatitis C, Chronic|Liver Cirrhosis |
2008-10-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/12/2023 |
News Article |
A well-executed Caspase 8 market study takes into account the 8.1% CAGR forecasted for the Caspase 8 industry from 2023 to 2030. |